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The FMS-like tyrosine kinase 3 (FLT3) is highly expressed in
acute myeloid leukemia (AML). Internal tandem duplications
(ITD) of the juxtamembrane domain lead to the constitutive
activation of the FLT3 kinase inducing the activation of multiple
genes, which may result in the expression of leukemia-
associated antigens (LAAs). We analyzed the regulation of
LAA in FLT3-wild-type (WT)- and FLT3-ITD
þ myeloid cells to
identify potential targets for antigen-speciﬁc immunotherapy
for AML patients. Antigens, such as PR-3, RHAMM, Survivin,
WT-1 and PRAME, were upregulated by constitutively active
FLT3-ITD as well as FLT3-WT activated by FLT3 ligand (FL).
Cytotoxic T-cell (CTL) clones against PR-3, RHAMM, Survivin
and an AML-directed CTL clone recognized AML cell lines and
primary AML blasts expressing FLT3-ITD, as well as FLT3-WT
þ
myeloid dendritic cells in the presence of FL. Downregulation of
FLT3 led to the abolishment of CTL recognition. Comparing our
ﬁndings concerning LAA upregulation by the FLT3 kinase with
those already made for the Bcr-Abl kinase, we found analogies
in the LAA expression pattern. Antigens upregulated by both
FLT3 and Bcr-Abl may be promising targets for the develop-
ment of immunotherapeutical approaches against myeloid
leukemia of different origin.
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Introduction
The FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase is
highly expressed by malignant cells in most cases of acute
myeloid leukemia (AML) and acute B-lineage leukemia (ALL).
1,2
In addition, FLT3 mutations belong to the most frequent somatic
alterations in AML and occur in approximately 30% of AML
patients.
3 The most common forms of mutant FLT3 are internal
tandem duplications (ITDs) in the juxtamembrane domain. This
duplication shows strong variations in length of 3 to more than
400bp between different patients.
4,5 The FLT3-ITD leads to the
constitutive activation by ligand-independent phosphorylation
of the receptor.
3 It has been shown in clinical studies that AML
patients harboring FLT3-ITD mutations have a poor prognosis.
6,7
Several small-molecule inhibitors of FLT3 have been developed
and are currently in different stages of clinical development,
including Sorafenib and SU5416.
8–10 Although treatment with
FLT3 inhibitors results in clinical responses in relapsed AML
with activating FLT3 mutations, the reduction in peripheral
blood and bone marrow blasts is only transient.
10–16 Combina-
tion therapies of FLT3 inhibitors and conventional chemother-
apy are currently being studied.
17 However, the insensitivity
of quiescent leukemic stem cells towards kinase inhibitors
may lead to the selective outgrowth of these cells and ﬁnally to
disease relapse even after years of continuous treatment.
T lymphocytes have the potential to eliminate the AML stem
cell. Proof of principle has been shown in an exceptional
clinical situation where donor lymphocyte infusions can induce
complete cytogenetic remissions of AML relapsed after allo-
geneic stem cell transplantation.
18 The donor’s T lymphocytes
include allo-restricted T cells, which may ideally combine
antigen speciﬁcity, high avidity and a superior leukemia–lytic
function. However, most of the allo-restricted T cells display
broad peptide speciﬁcity or even a peptide-independent human
leukocyte antigen (HLA)-dominant binding, both characteristics
leading to a wide reactivity and potentially to graft-versus-host
disease. Besides, the risk of graft-versus-host disease rises if
target antigens are widely expressed in the body. Therefore, the
current immunotherapeutic concepts focus on targeting those
antigens that are preferentially or even exclusively expressed by
AML blasts, including the AML stem cell.
Graf et al.
19 successfully generated cytotoxic T cells (CTLs)
highly speciﬁc for an HLA-A*0101 (HLA-A1)-restricted epitope
derived from the FLT3-ITD of one AML patient showing that the
FLT3-ITD is a potential target antigen for immunotherapeutic
approaches. However, the variations in the length of the ITD
imply the problem of having to ﬁnd an individual antigenic
epitope for each individual patient.
4 An alternative approach to
circumvent this problem may lie in the observation that the
likewise constitutively active tyrosine kinase Bcr-Abl expressed
in Philadelphia
þ chronic myeloid leukemia (CML) upregulates
immunogenic leukemia-associated antigens (LAA).
20 Some of
the Bcr-Abl-regulated LAA, such as PR-3 and Wilms tumor
protein (WT)-1, are also expressed in AML. Moreover, for PR-3
and WT-1, it has been shown that they spontaneously activate T
cells in AML patients, indicating the immunogenicity of these
antigens.
21 On the basis of these ﬁndings, we asked the question
as to whether LAA are also regulated by FLT3-WT and/or FLT3-
ITD in AML.
In this study, we show that a panel of LAA, such as PR-3,
Survivin and RHAMM, is upregulated by constitutively active
FLT3-ITD. Moreover, the activation of non-mutated FLT3 upon
stimulation with FLT3 ligand (FL) leads to the upregulation of the
same LAA. Vice versa, treatment of FLT3-WT
þ leukemia cells
with FLT3-small interfering RNA (siRNA) leads to the down-
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downregulation was also observed after treatment of FLT3-ITD
þ
leukemia cells with the FLT3 inhibitor Sugen SU5416. To prove
the functional relevance of FLT3-regulated LAA as immunological
targets, we used LAA-reactive CTL clones as effector cells.
Indeed, CTL clones speciﬁc for PR-3, Survivin and RHAMM
recognized various myeloid target cells harboring the activated
FLT3 kinase. The strong dependence of CTL killing on the FLT3
activation status indicates the relevance of FLT3-regulated LAA as
promising targets for T-cell-based immunotherapy.
Materials and methods
Cell culture
The human leukemia cell lines RS4;11 and MV4;11 (obtained
from the DSMZ, Braunschweig, Germany) carry the chromo-
somal translocation t(4;11)(q21;q23), but express different
MLL-AF4 variants owing to different break points. Further
leukemic cell lines used in this study were the cell lines K562
and K562 transfected with HLA-A*0201 (HLA-A2) (generous gift
from Th Wo ¨lfel, Klinikum der Johannes-Gutenberg-Universita ¨t,
Mainz, Germany) and BV-173 (DSMZ). The TAP-defective HLA-
A2
þ T2 cell line was provided by P Cresswell (Yale University
School of Medicine, New Haven, CT, USA). The B lympho-
blastoid cell lines (LCLs) were generated by EBV transformation
of peripheral blood B cells from healthy donors.
MV4;11, K562tA2, BV-173 and T2 cells were cultured in
RPMI 1640 (Invitrogen, Carlsbad, CA, USA). RS4;11 cells were
maintained in a-minimum essential medium. All media were
supplemented with 100U/ml penicillin, 100mg/ml strepto-
mycin, 2mM glutamine and 10% fetal calf serum.
The expression of HLA-A2 was conﬁrmed by ﬂuorescence-
activated cell sorting (FACS) analyses with a ﬂuorescein
isothiocyanate-conjugated anti-HLA-A2 monoclonal antibody
(BD Pharmingen, San Diego, CA, USA). For interferon (IFN)-g
treatment, the medium was supplemented with 100U/ml IFN-g
48h before the functional assays.
Generation of CTL clones
Peripheral blood mononuclear cells (PBMCs) were derived from
healthy donors and AML patients. Isolation of CD8
þ Tc e l l s
occurred via magnetic-activated cell sorting (Miltenyl Biotec,
Bergisch Gladbach, Germany) after indirect antibody staining.
The isolated HLA-A2
  CD8
þ T cells were repetitively stimulated
with allogenic HLA-A2
þ dendritic cells (DCs) loaded with 10mgo f
the HLA-A2-restricted peptide epitope PR-3169 177 (VLQELNVTV),
RHAMM165 173 (ILSLELMKL) or Survivin95 104 (ELTLGEFLKL).
CD8
þ T cells and peptide-pulsed DCs were co-cultured in
200ml AIM-V medium in a stimulator to a response ratio of 1: 20
in 96-well round-bottom plates with 5% human AB-Serum (Milan
Analytica, LaRoche, Switzerland), 1000U/ml interleukin (IL)-6 and
10ng/ml IL-12. Restimulation was set up in the presence of 5ng/ml
IL-7 and 100U/ml IL-2. After two stimulations, the proliferating
T cells were stained with HLA-A2/PR-3169 177,H L A - A 2 /
RHAMM165 173 and HLA-A2/Survivin95 104 multimers, respec-
tively, and the speciﬁc T cells were FACS sorted with a MoFlo cell
sorter (Cytomation, Fort Collins, CO, USA)
22 and cloned by limiting
dilution in ﬁve 96-well plates. The expansion of the T-cell clones
occurred in the presence of anti-CD3, IL-15, IL-2 and irradiated
LCL and PBMC as feeder cells.
IFN-g ELISpot assay
The production of IFN-g was determined in an ELISpot assay.
ELISpot membrane plates (Millipore, Bedford, MA, USA) were
coated overnight with an IFN-g-speciﬁc antibody (Mabtech AB,
Stockholm, Sweden). Target cells (2 10
4 cells per well) and
CTL (5 10
3 cells per well) were washed twice in RPMI medium
(Invitrogen) before seeding them onto the ELISpot plates. After
24h incubation at 371C, the spots were assessed using
antibodies against IFN-g, and then stained with AEC (3-amino-
9-ethylcarbazole; Sigma-Aldrich, St Louis, MO, USA) staining
solution. The number of spots was counted by using an
automated ELISpot reader system (KS ELISpot, Carl Zeiss, Jena,
Germany).
Enzyme-linked immunosorbent assay
To detect the IFN-g production of the CTL clones, 2 10
4 T
cells per well were co-cultured with 1 10
4 target cells in
96-well round-bottom plates at 371C. After 24h, supernatants
were collected and IFN-g production was determined using a
commercially available IFN-g enzyme-linked immunosorbent
assay (ELISA) kit (BD BioSciences International, San Jose, CA,
USA).
Cytotoxicity assay
Cytolytic activity was analyzed in a standard 4h chromium
release assay as described.
23 In short, the tumor cell lines
(5 10
5 cells in 100ml of fetal calf serum) were incubated with
100mCi of
51Cr for 1.5h at 371C, washed and used as target
cells. Peptide-loaded T2 cells were ﬁrst labeled with
51Cr for
1.5h at 371C and then loaded with the respective peptide
(10mg/ml) for an additional hour at room temperature. As
negative controls (ctrls),
51Cr-labeled T2 cells were loaded with
the HLA-A2-restricted peptide HIVpol476 484 (ILKEPVHGV).
The
51Cr-labeled targets were cultured with the T cells in RPMI
1640 with 10% fetal calf serum at 200ml per well in V-bottom,
96-well tissue culture plates (Greiner, Greiner Bio-One,
Frickenhausen, Germany). For evaluating the efﬁcacy of
CTL-mediated lysis, the T cells were serially diluted and then
co-cultured with a ﬁxed amount of target cells, resulting in
graded E:T ratios. For testing functional T-cell receptor (TCR)
avidity, the T cells were plated at a ﬁxed E:T ratio of 30:1 while
the peptide concentration was titrated.
After 4h of co-culturing the effector and target cells at 371C,
100ml of supernatant were collected and radioactivity was
measured in a g-counter. The killing was calculated as the
percentage of speciﬁc
51Cr release using the equation percen-
tage of speciﬁc lysis¼((sample release–medium release)/
(maximal release–medium release)).
siRNA treatment
The siRNA SMARTpool containing four pooled siRNA duplexes
directed against FLT3 (catalog no. M-003137-02-0005) and a
nonspeciﬁc siRNA (catalog no. D-001206-13-20) were
purchased from Thermo Science and Perbio (Thermo Fisher
Scientiﬁc, Waltham, MA, USA), respectively.
The transfection of siRNA was performed using the Nucleo-
factor system (Amaxa, Cologne, Germany) according to the
manufacturer’s instructions. The knockdown of the speciﬁed
protein was determined by FACS analyses.
RNA isolation and reverse transcription–polymerase
chain reaction
Total RNA was isolated using the RNeasy mini kit according to
the manufacturer’s instructions (Qiagen, Hilden, Germany). The
RNA was reverse transcribed using Moloney murine leukemia
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following primers were used: b-actin (sense: 50-GGGACCTGAC
TGACTACCTCAT-30; antisense: 50-ATAGTCCGCCTAGAAGCA
TTTG-30); PRAME (sense: 50-CTGTACTCATTTCCAGAGCCA
GA-30; antisense: 50-TATTGAGAGGGTTTCCAAGGGGTT-30);
PR-3 (sense: 50-CGGCCACATAACATTTGCAC-30; antisense:
50-TGGCACATCCCCAGATCAC-30); RHAMM (sense: 50-CAGGT
CACCCAAAGGAGTCTC-30;a n t i s e n s e :5 0-CAAGCTCATCCAGT
GTTTGC-30); Survivin (sense: 50-ACCACCGCATCTCTACATT
C-30; antisense: 50-GCTCTTTCTCTGTCCAGTTTC-30); and WT-1
(sense: 50-TAACCACACAACGCCCATC-30; antisense: 50-AAAAC
CTTCGTTCACAGTCC-30). The polymerase chain reaction (PCR)
products were electrophoresed on a 2% agarose gel and stained
with ethidium bromide.
Flow cytometry
Flow cytometry was performed using HLA-A2/PR-3169 177,
HLA-A2/RHAMM165 173 and HLA-A2/Survivin95 104 multi-
mers, and anti-human CD8 monoclonal antibody, ﬂuorescein
isothiocyanate conjugated (Immunotech, Marseille, France).
Fluorescence analyses were performed with the Coulter Epics
XL ﬂow cytometer (Coulter Electronics, GmbH, Krefeld,
Germany) and documented with the FlowJo software (Tree Star,
Ashland, OR, USA).
RESULTS
The LAA PR-3, RHAMM, Survivin, WT-1 and PRAME
are upregulated by the FLT3 receptor tyrosine kinase
First we analyzed whether the FLT3 kinase has an inﬂuence on
the expression of the LAA PR-3, RHAMM, WT-1, PRAME and
Survivin that are known to be expressed in AML.
24–29 As
examples for the FL-dependent FLT3-WT and the constitutively
active FLT3-ITD variant, we used the two different human acute
leukemia cell lines RS4;11 and MV4;11, which endogenously
express the FLT3-WT and FLT3-ITD, respectively.
In RS4;11 leukemia cells, the administration of FL increased
the expression levels of the LAA PR-3, RHAMM, WT-1, PRAME
and Survivin from low/intermediate levels before FL treatment to
high levels after incubation with FL (Figure 1a). This experi-
mental ﬁnding indicates the dependency of these LAA on the
activity of the FLT3 kinase. To further examine this ﬁnding, we
made an approach using the RS4;11 leukemia cells transfected
with siRNA against FLT3 and analyzed the expression of the LAA
PR-3, RHAMM, WT-1, PRAME and Survivin in the presence of
FL. Following treatment with FLT3-siRNA, the RS4;11 cells
showed a marked downregulation of these LAA even in the
presence of FL. The transfection of RS4;11 cells with the
irrelevant ctrl-siRNA in the presence of FL did not result in any
downregulation of LAA expression compared with that after
exclusive treatment with FL (Figure 1b).
In MV4;11 leukemia cells, in which the FLT3 kinase is
constitutively active, we detected a permanently high expres-
sion of the different LAA (Figure 1c). Culturing these cells with
SU5416, a known inhibitor of the FLT3-ITD activity, reduced the
expression of Survivin, an antigenic protein that has already
been known to be upregulated by the FLT3 kinase activity.
30,31
In addition, we documented decreasing levels of the expression
of PRAME, WT-1, RHAMM and PR-3 after an incubation of
48–72h. On the basis of these ﬁndings, we conclude that active
FLT3 kinase upregulates the expression of the LAA PR-3,
RHAMM, WT-1, PRAME and Survivin.
The correlation between the activity of the FLT3 kinase and
the expression of different LAA underlines the signiﬁcance of
these antigens for the development of immunotherapeutic
approaches against myeloid leukemia.
CTL clones against the LAA PR-3, RHAMM and Survivin
recognize and lyse leukemia cell lines and primary AML
blasts
On the basis of our ﬁndings that FLT3-expressing cell lines are
able to upregulate the LAA PR-3, RHAMM, WT-1, PRAME and
Survivin, our aim was the generation of CTL clones directed
against HLA-A2-restricted epitopes of these LAA. For this
purpose, CD8
þ T lymphocytes from healthy donors were
stimulated with allogeneic DCs loaded with the peptides
PR-3169 177, Survivin95 104, WT-1126 134, PRAME300 309 or
RHAMM165 173. Following repetitive stimulations, the amount
of PR-3169 177-, Survivin95 104- and RHAMM165 173-speciﬁc T
cells could be increased to numbers that permitted the
visualization, sorting with HLA-A2/peptide multimers and
cloning by limiting dilution. Sixty-two CTL clones grew in the
approach stimulated with PR-3169 177 from which after further
testing two proved to be tumour reactive. In the case of
Survivin95 104, one of 25 CTL clones tested was able to lyse
Survivin-expressing tumor cells. For RHAMM165 173, we got
three tumor-reactive out of 48 potential clones. Figure 2a
Figure 1 Inﬂuence of the FLT3 kinase on the expression of the LAA PR-3, RHAMM, WT-1, PRAME and Survivin. (a) RS4;11 (FLT3-WT
þ) cells
were treated with FL for a time period of 72h and the expression of the LAA PR-3, RHAMM, WT-1, PRAME and Survivin was documented via
RT–PCR at 8, 12, 24, 48 and 72h after treatment. (b) RS4;11 (FLT3-WT
þ) cells were treated with FL, FLT3-siRNA and/or ctrl-siRNA for 72h, and
the expression of the LAA PR-3, RHAMM, WT-1, PRAME and Survivin was analyzed by RT–PCR. (Lanes 1–4 show the expression of the different
tumor antigens PR-3, RHAMM, WT-1, PRAME and Survivin in RS4;11 cells treated with FL (lane 1), in RS4;11 cells treated with FLT3-siRNA (lane
2), in RS4;11 cells treated with ctrl-siRNA (lane 3) and in RS4;11 cells without FL (lane 4).) (c) MV4;11 (FLT3-ITD
þ) cells were treated with the
FLT3 kinase inhibitor SU5614 for 72h, and the expression of the LAA PR-3, RHAMM, WT-1, PRAME and Survivin was documented via RT–PCR at
different time points after treatment. The three ﬁgures are composed of different gels.
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CTL clone with the respective multimer.
The peptide speciﬁcity of the respective clones was conﬁrmed
in an IFN-g ELISA, in which T2 cells loaded with PR-3169 177,
Survivin95 104, RHAMM165 173 or the irrelevant peptide
HIVpol476 484 were used as target cells. As shown in
Figure 2b, the different CTL clones secreted high amounts of
IFN-g after incubation with the respective relevant, but not with
the irrelevant peptide. In the same test, we analyzed whether the
different CTL clones were able to recognizse endogenously
processed PR-3169 177, Survivin95 104 and RHAMM165 173,
respectively. Therefore, the HLA-A2
þ K562tA2 leukemia cells
known to express PR-3, Survivin and RHAMM were used as
target cells. The reactivity pattern of the different clones is
shown in Figure 2b. The different CTL clones were able to
recognize K562tA2 cells, whereas there was no recognition of
K562 cells used as negative ctrl. The lytic activity was
determined in a
51Cr release assay. Lysis of T2 cells loaded
Figure 2 CTL clones against PR-3, RHAMM, and Survivin, respectively, recognize the corresponding peptide epitopes. (a) FACS staining of the
different CTL clones with the respective multimers. (b) The different CTL clones were co-cultivated with T2 cells loaded with PR-3169 177,
RHAMM165 173, Survivin95 104 or HIVpol476 484, K562tA2, K562 or MCF7. The IFN-g concentration of the supernatant was determined by ELISA.
(c) Differential lytic activity of HLA-A2-restricted PR-3169 177-, RHAMM165 173- or Survivin95 104-directed CTL clones against T2 cells loaded
with the respective peptide (E) and HLA-A2
þ K562tA2 cells (’). T2 cells loaded with the irrelevant peptide HIVpol476 484 (m) and K562 cells
(K) were used as negative ctrl. (d) Functional avidity of CTL clones was determined by the recognition of T2 cells pulsed with graded amounts of
peptides. (e) The different CTL clones were co-cultivated with FLT3-ITD
þ blasts of an HLA-A2
þ AML patient or with blasts of an HLA-A2
  AML
patient. The IFN-g concentration of the supernatant was determined by ELISA.
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between 45 and 100% at increasing E:T ratios, whereas there
was no recognition of T2 cells pulsed with the irrelevant peptide
HIVpol476 484. The leukemic cell line K562tA2 was lysed with a
maximum of about 55% at an E:T ratio of 10:1 (Figure 2c, left).
The Rhamm-speciﬁc CTL clone JG9E5 showed about 100% lysis
of RHAMM165 173-loaded T2 cells at higher E:T ratios and up to
40% lysis of K562tA2 cells (Figure 2c, middle). The lysis of T2
cells loaded with Survivin95 104 by CTL clone SK1 was between
25 and 90% at increasing E:T ratios. K562tA2 cells were lysed
with a maximum of about 40% (Figure 2c, right).
Furthermore, the functional avidities of the CTL clones toward
the peptides PR-3169 177, Survivin95 104 and RHAMM165 173
were assessed by the recognition of serially diluted amounts of
the respective peptides (10
 5–10
 16 M) loaded onto T2 cells in
an IFN-g ELISA. The PR-3-speciﬁc CTL clone displayed a rather
high avidity toward the PR-3169 177 peptide with a half-
maximum IFN-g secretion of 10
 10 (Figure 2d, left). The
RHAMM- and the Survivin-reactive CTL clones have a relatively
low avidity with a half-maximum IFN-g secretion of about
10
 7–10
 6 (Figure 2d, middle, right).
On the basis of our ﬁndings that FLT3-expressing cell lines
upregulate the LAA PR-3, RHAMM, WT-1, PRAME and Survivin,
we were led to question whether our CTL clones reactive against
PR-3, Survivin and RHAMM were able to recognize leukemic
blasts. Hence, we co-cultivated the three CTL clones with
primary blasts of an HLA-A2
þ patient with FLT3-ITD
þ AML.
Blasts of an HLA-A2
  AML patient served as negative ctrl. As
shown in Figure 2e, the CTL clones performed high IFN-g
secretion only in the presence of HLA-A2
þ, FLT3-ITD
þ blasts,
but not in the presence of HLA-A2
  blasts.
Leukemia-reactive CTL clones are generated by
stimulation with blast-derived DC
On the basis of our ﬁndings, we were led to question whether
FLT3-ITD
þ leukemic blast-derived DCs (DCAML) were capable
of inducing a primary CTL response. In this approach, we
stimulated HLA-A2
  CD8
þ T lymphocytes from a healthy donor
with allogeneic DCAML of a 71-year-old HLA-A2
þ female
patient with FLT3-ITD
þ AML. The expression of the LAA PR-3,
Survivin, WT-1, PRAME and RHAMM by these DCAML has been
documented by RT–PCR (Supplementary Figure 1A). The
dependency of this expression on the FLT3 kinase activity could
be shown indirectly by the downregulation of IFN-g secretion by
the respective clones following treatment of DCAML with
SU5416, a known inhibitor of the FLT3 kinase activity
(Supplementary Figure 1B). After two stimulations, we did an
IFN-g ELISpot assay with T2 cells pulsed with the AML-
associated peptides PR-3169 177, Survivin95 104, WT-1126 134,
PRAME300 309 or RHAMM165 173, HIVpol476 484, as well as
with K562tA2 and K562 to test the speciﬁcity of the different
T-cell populations in the 96-well plates. There were no T cells
speciﬁc for one of the peptides tested, so we cloned T cells
recognizing K562A2, but not K562 (data not shown). The
reactivity pattern of three of the resulting CTL clones (CTLAML)i s
shown in Figure 3. The three CTLAML clones showed high
reactivity against the HLA-A2
þ leukemia cell lines K562tA2 and
BV173, but no recognition of K562 (Figure 3a) in an IFN-g
ELISpot. Furthermore, we wanted to know whether the
recognition of the CTLAML clones is speciﬁcally restricted to
HLA-A2
þ leukemic blasts and not to PBMC of a healthy donor.
As depicted in Figure 3b, there was only low or no reactivity
against HLA-A2
þ PBMC and HLA-A2
  blasts. In contrast,
there was a marked IFN-g secretion when co-cultivated with
HLA-A2
þ leukemic blasts (Figure 3b).
DCs transfected with FLT3-ITD are recognized by CTL
clones against PR-3, RHAMM and Survivin, as well as
by CTLAML clones
We wanted to know whether downregulation of the FLT3 kinase
is also leading to a lower recognition of FLT3
þ cells by our
isolated CTL clones. As we do not have any FLT3
þ cell lines, we
used HLA-A2
þ DCs from a healthy donor. For testing the FLT3-
WT and the constitutively active mutant variant FLT3-ITD, the
Figure 3 CTL clones stimulated with HLA-A2
þ ITD
þ DCAML recognize leukemia cell lines and blasts. CD8
þ T cells from a healthy HLA-A2
 
donor were primed with allogeneic HLA-A2
þ DCAML and speciﬁc T cells were cloned. (a) In an IFN-g ELISpot, the three CTLAML clones were
co-incubated with K562tA2, K562 and HLA-A2
þ BV173 cells, and the resulting spots were counted. (b) An IFN-g ELISpot was performed using
allogeneic HLA-A2
  PBMC and blasts, as well as HLA-A2
þ blasts as targets and the three CTLAML clones as effector cells.
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analyze if FLT3 was active in DCs transfected with FLT3-WT, we
compared recognition of DCs either treated or not treated with
FL by the CTL clones directed against PR-3, RHAMM, Survivin
and the CTLAML clones. As depicted in Figure 4, there was no or
only little IFN-g secretion of the different CTL clones in the
presence of untreated FLT3-WT DCs. The CTL clones directed
against PR-3, RHAMM and Survivin showed high reactivity
against DCs treated with FL (Figure 4a). In contrast, only one of
the CTLAML clones (clone no. 3) secreted some IFN-g when
incubated with DCs treated with FL (Figure 4b). The three
peptide-speciﬁc clones and the CTLAML clone no. 3 displayed
high FL-independent recognition of ITD
þ DCs. To see the effect
of downregulation of FLT3-WT, we used the FLT3-siRNA that
we already used in RS4;11 cells (Figure 1b). Following treatment
of the DCs with FLT3-siRNA, no recognition could be observed
by any of the clones independently of FL. With these experi-
mental settings, we were able to further conﬁrm our hypothesis
that the expression of the LAA PR-3, RHAMM and Survivin is
regulated by active FLT3.
In contrast to CTLAML clone no. 3, which also seems to have
an FLT3-dependent recognition, the CTLAML clone nos 8 and 12
did not show any reactivity against DCs nucleofected with
FLT3-WT or FLT3-ITD.
CTL clones against PR-3, RHAMM and Survivin
recognize DCs transfected with Bcr-Abl-WT, but not
DCs transfected with Bcr-Abl-KD
Our ﬁndings concerning the upregulation of different LAA by the
active FLT3 kinase are in accordance with the observations
about the immunogenicity of the Bcr-Abl kinase made by our
group.
20 It has been shown that the tyrosine kinase activity of
Bcr-Abl leads to enhanced expression of some CML-associated
antigens, for example, PR-3. In the meantime, we could also
detect an upregulation of RHAMM and Survivin in Bcr-Abl
þ
cells. As we now have T-cell clones against these LAA, which
recognize cells expressing FLT3, we wanted to know whether
these clones are also reactive against Bcr-Abl-WT
þ cells. For
comparison of the active and inactive form of Bcr-Abl, we
transfected DCs with Bcr-Abl-WT-mRNA or a kinase-deﬁcient
Bcr-Abl-mRNA (KD) as described before.
20
The reactivity of the different peptide-speciﬁc T-cell clones
and the CTLAML clones against the transfected DCs were
documented by analyzing their IFN-g release (Figure 5). The
pattern of T-cell-derived IFN-g release shows a high reactivity of
the different peptide speciﬁc CTL clones and the CTLAML clone
no. 3 against Bcr-Abl-WT
þ DC, but not against Bcr-Abl-KD
þ
DCs. Interestingly, this was also true for the two other CTLAML
clones that did not recognize FLT3-WT-transfected DCs (Figures
4b and 5).
DISCUSSION
Cytotoxic T lymphocytes have the potential to eliminate
malignant stem cells, even if they are quiescent. Immunother-
apeutic approaches are being developed based on antigen-
speciﬁc T lymphocytes, such as antigen vaccination or adoptive
T-cell transfer. As FLT3-ITD is partially expressed by CD34
þ/
CD33
  AML progenitors, sequences from FLT3-ITD itself may
serve as ideal leukemia-speciﬁc epitopes for leukemia-speciﬁc T
lymphocytes.
32 Indeed, from one patient with FLT3-ITD
þ, AML
leukemia-speciﬁc CTL clones have been isolated that recognize
Figure 4 Reactivity of CTL clones directed against PR-3, RHAMM and Survivin, as well as CTLAML clones towards DCs nucleofected with
FLT3-WT plus and minus FLT3-siRNA or FLT3-ITD. All approaches were carried out with and without the addition of FL. (a, b) HLA-A2
þ DCs from
a healthy donor were nucleofected with FLT3-WT-mRNA or FLT3-ITD-mRNA and co-cultivated with the different CTL clones with and without the
addition of FL. Furthermore, the FLT3-WT
þ DCs were additionally transfected with FLT3-siRNA. The supernatants were tested in an IFN-g ELISA.
(a, b) show the results of the ELISA with the CTL clones directed against PR-3, RHAMM and Survivin, as well as with the CTLAML clone nos 3, 8 and
12.
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FLT3-ITD sequence.
19 However, the strong variation in length
of ITD duplications between AML patients implies the problem
to ﬁnd T-cell epitopes for every single patient to design an
individual immunotherapy. In AML, several shared antigens
have been identiﬁed, which can potentially serve as targets for
cytotoxic T lymphocytes, such as PR-3, RHAMM, WT-1, PRAME
and Survivin.
24–29 Until now, the expression pattern of these
AML-associated antigens and their relevance for the CTL-
mediated elimination of AML stem cells is not entirely under-
stood. As the FLT3-ITD is active in early progenitor AML cells,
we asked the question as to whether some of the shared antigens
are dependent on the activated form of the mutant FLT3 kinase.
In this study, we analyzed the expression of PR-3, RHAMM,
WT-1, PRAME and Survivin in an FLT3-WT
þ leukemia cell line
with and without the addition of FL. There was a weak basic
expression of the ﬁve LAA analyzed. The addition of FL,
however, resulted in a stronger LAA expression being the ﬁrst
hint for an existent association between FLT3 activity and LAA
regulation. This could be conﬁrmed by the downregulation of
FLT3 activity, with FLT3-siRNA subsequently lowering the
expression of the LAA analyzed. To test the inﬂuence of a
constitutively active mutant variant of FLT3, we analyzed the
LAA expression in an FLT3-ITD
þ leukemia cell line. These
cells showed a high level of LAA corresponding to that of the
FLT3-WT
þ leukemia cell line treated with FL. The inhibition of
the constitutively active FLT3-ITD by SU5614, a known
inhibitor of the FLT3-ITD activity,
30 showed an effect analogous
to that achieved after treatment of FLT3-WT
þ cells with FLT3-
siRNA. These data document for the ﬁrst time that the expression
of PR-3, RHAMM, WT-1, PRAME and Survivin is upregulated
upon activation of the FLT3 kinase.
We next asked the question as to whether the upregulation of
LAA by the activation status of FLT3 inﬂuenced the T-cell-
mediated lysis of leukemia cells. First, we established a panel of
allo-HLA-A2-restricted CTL clones speciﬁc for PR-3, RHAMM
and Survivin. To effectively stimulate and select T cells against
these self-antigens, we took advantage of an HLA mismatch
between DCs and T cells by using DCs from an HLA-A2
þ donor
as stimulator cells and T cells from an HLA-A2
  donor as
responder cells.
33,34 For further experiments, we expanded
those CTL clones that displayed a ﬁne speciﬁcity against the
respective peptides as shown by IFN-g release and lytic activity.
The selected CTL clones HK5, JG9ES and SK1 recognized the
K562tA2 leukemic cell line expressing PR-3, RHAMM and
Survivin. As assumed, FLT3-ITD
þ AML blasts were also
recognized by these CTL in an HLA-A2-restricted manner. To
answer the important question as to whether T-cell recognition
of myeloid cells is dependent on the FLT3-modulated expression
level of their antigens, we used myeloid DCs as target cells. The
herein generated monocyte-derived DCs transfected with
FLT-WT were not recognized by the antigen-speciﬁc CTL clones
HK5, JG9ES and SK1. FMS-like tyrosine kinase 3-WT
þ DCs
were recognized upon FL stimulation, indicating that the
activation of the FLT3 kinase raised the expression level of
PR-3, RHAMM and Survivin above a certain threshold, which
further enabled the T cells to recognize their targets. Similarly,
CTL recognition could be induced when FLT3-WT
þ DCs were
transfected with the constitutively active FLT3-ITD. The
correlation between FLT3 activity and the upregulation of
CTL-deﬁned LAA points to the signiﬁcance of these antigens for
the physiological as well as the therapeutic relevance of
immune responses against acute leukemias.
35 Exemplarily, the
expression of RHAMM and PRAME have been shown to be
associated with a favorable clinical outcome in AML patients
and to induce T-cell responses.
29 Peptide vaccination trials
performed with RHAMM, PR-3 and WT-1 peptides resulted in
measurable immunological and clinical responses in patients
with different hematological diseases.
29,36–40
As a second approach to prove the immunological relevance
of FLT3-regulated antigens for targeting AML cells, we generated
DCs from AML blasts known to be able to stimulate leukemia-
reactive autologous T lymphocytes.
41,42 Following stimulation
of allogeneic HLA-A2
  CD8
þ T cells with HLA-A2
þ DCAML,
we isolated three different leukemia-reactive CTL clones. All of
the three established CTLAML clones recognized FLT3-ITD
þ
AML blasts in an HLA-A2-restricted manner. None of the HLA-
A2-restricted epitopes of the known LAA PR-3, RHAMM,
Survivin, PRAME and WT-1 was recognized by the CTLAML
clones. Of note, one of the three CTLAML clones (CTL no. 3)
Figure 5 Reactivity of CTL clones directed against PR-3, RHAMM and Survivin, as well as CTLAML clones towards DCs nucleofected with
Bcr-Abl-WT or Bcr-Abl-KD. The CTL clones were co-incubated with the respective DCs and an IFN-g ELISA was performed using the resulting
supernatant.
FLT3-regulated antigens
B Brackertz et al
7
Blood Cancer Journalsecreted IFN-g when stimulated with DCs harboring the active
form of the FLT3 kinase, such as FLT3-ITD-transfected DCs or
FL-stimulated FLT3-WT
þ DCs. This indicates that FLT3-regu-
lated antigens are able to stimulate primary T-cell responses
towards myeloid leukemia cells.
On the basis of our previous ﬁndings that the expression level
of some LAA, such as PR-3 and PRAME, is not only induced by
activated FLT3, but also by the constitutively active Bcr-Abl
kinase,
20 we next analyzed the recognition pattern of the herein
described AML-reactive CTL clones in response to monocyte-
derived DCs transfected with Bcr-Abl-WT or Bcr-Abl-KD. We
ﬁrst analyzed the IFN-g secretion by the PR-3-speciﬁc CTL clone
HK6 in response to HLA-A2-matched Bcr-Abl-WT
þ DCs versus
Bcr-Abl-KD
þ DCs. As postulated, the PR-3-speciﬁc CTL clone
released IFN-g in the presence of Bcr-Abl-WT
þ DC, but not in
the presence of Bcr-Abl-KD
þ DCs. Similarly, the RHAMM- and
Surivin-speciﬁc CTL clones both released high amounts of IFN-g
only in the presence of Bcr-Abl-WT
þ DCs. Interestingly, all
three CTLAML clones with yet undeﬁned antigen speciﬁcity
reacted strongly with Bcr-Abl-WT
þ DCs and only to a low
extent with Bcr-Abl-KD
þ DCs. Therefore, CTL clone nos 8 and
12 seem to recognize a LAA, which is regulated by the Bcr-Abl,
but not by the FLT3 kinase. In contrast, the antigen recognized
by CTL clone no. 3 is regulated by both the FLT3 and the Bcr-
Abl kinase. In summary, there are common as well as
differential antigen patterns induced on the activation of the
Bcr-Abl and FLT3 kinases. Our ﬁndings raise the question as to
whether the same and/or other LAAs are upregulated by
additional tyrosine kinases, for example, the NPM/Alk kinase.
In conclusion, antigens upregulated by kinases activated in
leukemia cells may be promising targets for the development of
T-cell-based immunotherapies against myeloid leukemia of
different origins. As the broad clinical application of adoptive
T-cell transfer is limited owing to the laborious procedure of
T-cell isolation and characterization, we will pursue an
alternative methodology whereby primary human T-cell popu-
lations are transduced with the LAA-reactive TCR of interest.
The herein presented CTL clones against FLT3- and Bcr-Abl-
regulated antigens, respectively, for example, PR-3 and
RHAMM, may serve as a source for leukemia-reactive TCR.
The TCR gene transfer is a convenient method to produce
antigen-speciﬁc T cells, further allowing that an individualized
therapy will be available for a mass of patients with FLT3
þ or
Bcr-Abl
þ myeloid leukemias.
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